Mesothelioma News and Research

RSS

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

PFAS in US water linked to increased cancer risk

A study links PFAS contamination in drinking water to increased cancer risks, highlighting significant impacts on digestive, endocrine, and respiratory systems.

16 Jan 2025

New biomarkers may offer a more sensitive approach for monitoring kidney health

Drug-induced kidney injury, or nephrotoxicity, is a common complication in clinical medicine that happens when drugs damage the kidneys.

6 Jan 2025

Clinical utility of carbonic anhydrase IX in diagnosing pleural mesothelioma

Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging.

27 Oct 2024

Engineered E. coli shows promise in cancer immunotherapy

Recent research has shown that certain forms of E. coli bacteria tend to colonize hypoxic areas of the body, including tumors, suggesting they might be playing a role in cancer therapeutics.

4 Oct 2024

Gut bacteria may influence immunotherapy success in mesothelioma patients

A cancer study has found that certain gut bacteria may influence whether or not a patient's immune system is successful in fighting mesothelioma, an aggressive form of cancer.

5 Sep 2024

EZH2's role in cancer progression and therapy explored

Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).

9 Aug 2024

Insilico Medicine's pan-TEAD inhibitor ISM6331 receives FDA IND clearance for mesothelioma treatment

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for the treatment of mesothelioma, following the grant of Orphan Drug Designation (ODD) in June 2024. It brings the total number of IND-approved molecules of Insilico to nine.

8 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

Asbestos exposure and carcinogenicity: A comprehensive review

Asbestos, a group of naturally occurring fibrous minerals, has been historically used for its durability and resistance to heat.

29 Jul 2024

Fox Chase Cancer Center researchers identify new targets for mesothelioma prevention

A new research perspective was published in Oncoscience (Volume 11) on May 23, 2024, entitled, "Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma."

19 Jul 2024

Triad of immune cells key to successful cancer immunotherapy, study finds

There's a frustrating fact about today's immunotherapies for cancer. While sometimes they work beautifully - completely eliminating or greatly reducing cancer in particular patients - other times they don't work at all. It's a mystery.

15 Jul 2024

Immunotherapy response assessment in malignant pleural mesothelioma: FDG-PET/CT vs. CT

A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, "Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma."

15 Jul 2024

Scientists identify over 5,000 genetic variants that enable certain cancers to thrive

Researchers performed saturation genome editing of the BAP1, whose dysfunction is related to cancer and impaired neurodevelopment.

10 Jul 2024

New analysis sheds light on cancer incidence and mortality trends in the UK

Trends in cancer incidence and deaths in the United Kingdom (UK) among individuals aged between 35 and 69 years.

14 Mar 2024

Innovative treatment increases survival of people with malignant mesothelioma, trial shows

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.

15 Feb 2024

Non-smokers' lung cancer among top five global cancer-related deaths in 2023

The development of lung cancer in individuals who have never smoked.

11 Jan 2024

Basal spot junctions: A new player in epithelial adhesion and hippo signaling

Australian researchers have discovered a new way that epithelial cells, which form layers in organs like the skin and stomach, attach to one another, and how they perceive growth signals at these attachments, helping them form tissues of the right size and shape.

21 Dec 2023

Asbestos exposure linked to higher incidence of lung cancers in naval personnel

A University of Adelaide and Oxford University study has discovered asbestos exposure led to a higher incidence of asbestos-related lung cancers in British and Australian naval personnel than in other armed forces.

14 Nov 2023

New drug shows promise in killing cancer cells with genetic vulnerability

Imagine the body's cells are well-behaved students in the classroom. The "teachers" are tumor suppressor genes, and they make sure cells follow the rules. But when tumor suppressor genes are away, cells may go astray.

1 Nov 2023